Eunkyung Shin

Eunkyung Shin

Auto-generated profile, based on publicly available information

Eunkyung Shin

Center for Vaccine Research, National Institute of Health, Korea Disease Control and Prevention Agency, CheongJu, Chungbuk, Republic of Korea

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Journal of Clinical Virology
Verified
Journal Article
Closed access
ESEunkyung Shin
Eunkyung Shin
JKJin Seok Kim
Jin Seok Kim
KOKyung Hwan Oh
Kyung Hwan Oh
SOSung Suck Oh
Sung Suck Oh
MKMunJu Kwon
MunJu Kwon
JKJunyoung Kim
Junyoung Kim

14 May 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ESEunkyung Shin
Eunkyung Shin
JYJin-Seung Yun
Jin-Seung Yun
YLYoung-Ran Lee
Young-Ran Lee
HCHye-Ran Cha
Hye-Ran Cha
SKSoo-Min Kim
Soo-Min Kim
HJHye-Sook Jeong
Hye-Sook Jeong
Mycobacterium tuberculosis infection accounted for 1.3 million deaths worldwide in 2022. Bacillus Calmette-Guérin (BCG) is the only licensed vaccine against tuberculosis (TB); however, it has limited protective efficacy in adults. In this study, we constructed a recombinant vaccinia virus expressing Ag85B from M. tuberculosis using a novel attenuated vaccinia virus (KVAC103). We then analyzed the immunogenicity of prime-boost inoculation strategies using recombinant KVAC103 expressing Ag85B (rKVAC85B) compared to BCG. In both rKVAC85B prime-boost and BCG prime-rKVAC85B boost inoculation regimens, rKVAC85B induced the generation of specific immunoglobulin G (IgG) and secretion of interferon-γ by immune cells. In vitro analysis of Mycobacterium growth inhibition revealed a comparable immune-mediated pattern of outcomes. Furthermore, bacterial loads in the lungs were significantly lower in mice inoculated with the BCG prime-rKVAC85B boost than in the BCG-only group following a rechallenge infection with both H37Rv and HN878 strains of M. tuberculosis. These findings collectively suggest that KVAC103, incorporated into a viral vector, is a promising candidate for the development of a novel TB vaccine platform that is effective against multiple M. tuberculosis strains, including H37Rv and HN878, and that rKVAC85B effectively stimulates immune responses against M. tuberculosis infection.

12 March 2025 in Public Health Weekly Report
Verified
Journal Article
Open access
PDF file
은신은경 신
은경 신
수김수민 김
수민 김
진윤진승 윤
진승 윤
소박소희 박
소희 박
HJHye-Sook Jeong
Hye-Sook Jeong
유김유진 김
유진 김
신은경, 김수민, 윤진승, 박소희, 정혜숙, 김유진. Public Health Weekly Report 2025;18:88-101. https://doi.org/10.56786/PHWR.2025.18.11suppl.7

7 July 2026 in Biomaterials
Verified
Journal Article
Open access
HJHayoon Jeong
Hayoon Jeong
GYGookjin Yoon
Gookjin Yoon
DLDong Woo Lee
Dong Woo Lee
HYHansang Yu
Hansang Yu
YKYu-Bin Kim
Yu-Bin Kim
YPYoon Jeong Park
Yoon Jeong Park
Messenger RNA (mRNA) vaccines require efficient delivery systems to reach antigen-presenting cells (APCs). Lipid nanoparticles (LNPs) are a standard delivery carrier. However, LNPs often accumulate in the liver and exhibit transient protein expression. These limitations can restrict their safety and immunogenic potential. Here, we developed a modular, peptide-based nanocomplex to overcome the current limitations. The system comprises three functional peptides: an RNA-binding peptide (RBP) for condensation, l-polyglutamic acid (PGA) for charge modulation, and an APC-targeting cell-penetrating peptide (A-CPP). This A-CPP features a newly discovered 7-mer immune cell-binding motif identified in this study. We optimized the physicochemical properties by systematically fine-tuning the ratios of these peptide modules. The optimized nanocomplex formed stable particles under 200 nm. Unlike LNPs, which showed significant liver accumulation, the peptide-nanocomplexes remained localized at the injection site and effectively drained to the lymph nodes. Furthermore, the peptide-nanocomplex retained mRNA expression for up to 7 days in vivo, whereas LNP-mediated expression diminished within 48 h. In mice immunized with SARS-CoV-2 spike mRNA, this prolonged antigen exposure elicited robust neutralizing antibody titers comparable to LNPs. Notably, the peptide-nanocomplex induced significantly higher CD8+ T cell responses than LNPs. Moreover, the peptide-nanocomplex demonstrated an excellent safety profile in vivo with no toxicity observed even after daily injections for two weeks at doses up to 200 times higher. This study establishes a data-driven fine-tuning strategy for peptide-based mRNA delivery. The resulting peptide-nanocomplex offers a safer, lymph node-targeted, and longer-lasting efficacy alternative to lipid-based carriers for next-generation vaccines.

30 March 2022 in The Korean Society for the Study of Lifelong Education
Verified
Journal Article
Closed access
YHYoung-Sup Hyun
Young-Sup Hyun
ESEun-Kyung Shin
Eun-Kyung Shin
????????????? ????????п??? ?ֿ? ????????????. Ư?? ?ֱٿ? ?ͼ? ????????????? ???? ???? ???? ?????? ?????ϰ? ?????Ͽ???, ???? ???ؿ????? ???? ?ڷ? ?????? Ȱ?뵵 Ȱ????????. ?????? ????????????? ???? ?????????? ?????? ???? ?????? ?پ缺, ????????????? ???? ?? ?????????????? ?߻??? ???? ???? ?Բ? ?????Ͽ???. ?̿? ?? ?????????? ???? ??????????? ?????? ?????????????? ?????? ?м??ϴ? ?????? ?????Ͽ???. ?????????? ?޼??ϱ? ????, ???? ??????????? ???? ?м??? ???? ???? 85???? ?????ϰ? 812???? ???????? Ȯ???Ͽ? ?м??? Ȱ???Ͽ???. ?????????????? ?????? ?м??ϱ? ???? ǥ?ú??????(MVT)?? ????ֺ?????(MMP)?? Ȱ???Ͽ???. ?м?????? ?????ϸ? ù°, MVT ?м?????? ??????, ??????????? ???????? ?ɰ??? ???? ?ƴ?????, ?????ֽ??ؾ? ?? ?????? ?????????????ǰ? ?߻??Ͽ???. ??°, ???????? ???? ???? MVT ?м?????? ???ϸ?, ???????α׷? Ư???? ???????????????? ?????? ?? ?? ???? ?????? ??Ÿ????. ??°, MMP ?м????, ????????? ???? ?????????????? ???? ???̰? ?????? ?? ?ִٴ? ???? Ȯ?εǾ???. ?̻??? ?м?????? ???? ??а? ?û????? ?????Ͽ???.